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Abstract 
Background: The ability of a malaria antigen to induce effective, long‑lasting immune responses is important for 
the development of a protective malaria vaccine. Plasmodium vivax merozoite surface protein‑8 (PvMSP8) has been 
shown to be immunogenic in natural P. vivax infections and produces both cell‑mediated and antibody‑mediated 
immunity. Thus, PvMSP8 has been proposed as a vaccine candidate following fusion with other merozoite antigens 
in blood stage vaccine design. Here, the long‑term responses of antibodies and memory B cells (MBCs) specific to 
PvMSP8 in individuals were monitored in a longitudinal cohort study.
Methods: Both cross‑sectional surveys and cohort studies were utilized to explore the persistence of antibody and 
MBC responses to PvMSP8. Antibody titers were detected in individuals with acute disease and those who recovered 
from an infection for 4 years. The dominant peptide epitope of PvMSP8 recognized by naturally acquired antibodies 
was examined to observe the durability of the post‑infection antibody response. PvMSP8‑specific MBCs were also in 
subjects 4 years post‑infection using an enzyme‑linked immunospot assay.
Results: The prevalence of antibodies to PvMSP8 was high during and after infection. The antibody levels in individ‑
ual responders were monitored for up to 12 months post‑infection and showed that most patients maintained their 
seropositive response. Interestingly, the anti‑PvMSP8 antibody responses stably persisted in some patients who had 
recovered from an infection for 4 years. Positive PvMSP8‑specific MBCs were also detected at 4 years post‑infection. 
However, analysis in these individuals showed no correlation with the presence or titer of circulating antibody.
Conclusion: PvMSP8 had the ability to induce a long‑term humoral immune response. The antibodies and MBCs 
specific for this antigen developed and persisted in subjects who acquired a natural P. vivax infection. Inclusion of the 
PvMSP8 antigen in blood stage vaccine design should be considered.
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Background
Highly effective malaria vaccines are required for use as 
part of a repertoire of tools for the elimination or eradi-
cation of malaria. Malaria vaccines are generally classi-
fied based on their target within the parasite lifecycle: (i) 
a pre-erythrocytic vaccine aims to prevent blood stage 
infections, (ii) a blood stage vaccine aims to clear para-
sitaemia and prevent clinical disease, and (iii) a transmis-
sion-blocking vaccine aims to prevent the infection of 
mosquitoes and interrupt the malaria transmission cycle 
[1]. The leading vaccine candidate against the blood stage 
of Plasmodium vivax is Duffy binding protein region II 
(DBPII), the only candidate antigen that has currently 
reached clinical trials [2]. However, an obstacle to this 
vaccine’s efficacy is strain-specific immunity due to the 
presence of DBPII allelic variation [3]. The identification 
of conserved epitopes among DBPII variants has become 
a substantial challenge in the development of DBPII-
based vaccines. Moreover, the increasing recognition of 
P. vivax infections in Duffy-negative individuals suggests 
that there is an alternative pathway for the parasites to 
invade red blood cells. Together, this suggests that a com-
bination of antigens would enhance the efficacy of a vivax 
malaria vaccine and more likely lead to broadly protec-
tive immune responses.
Merozoite surface protein 8 (MSP8) is a glycosylphos-
phatidylinositol (GPI)-anchored protein expressed in 
blood stage malaria parasites. MSP8 possesses two epi-
dermal growth factor (EGF)-like domains at the C termi-
nus, and these modules are considered potential targets 
of protective immunity. High antigenicity of MSP8 has 
been shown in both Plasmodium yoelii and Plasmodium 
falciparum. In P. yoelii, immunization with full-length 
MSP8 fused with MSP1-19 induced a T cell response and 
high levels of protective antibodies against these two anti-
gens [4]. Plasmodium falciparum MSP8 (PfMSP8) was 
found to be immunogenic during natural infections. Sera 
from malaria-exposed patients appear to recognize B cell 
epitopes within the first 350 amino acids of PfMSP8 that 
contain an Asn/Asp-rich domain [5, 6]. A recombinant 
PfMSP8 protein induced strong T and B cell responses in 
immunized mice [7]. Importantly, immunization with an 
MSP8/merozoite surface protein 1 (MSP1) chimera elic-
its an antibody response that inhibits P. falciparum blood 
stage growth in vitro, indicating that MSP8 represents a 
potential malaria-specific carrier protein to enhance the 
immunogenicity of neutralizing B cell epitopes in the 
19-kDa C terminal domain of MSP1 [7–9]. Based on the 
results from limited studies of P. vivax, patients predomi-
nantly produce the IgG2 antibody subtype against MSP8 
protein. The total IgG response to PvMSP8 increased 
up to day 7 and then decreased slightly within a month. 
Anti-PvMSP8 antibodies are stably sustained for up to 
12  years post-recovery in patient samples from regions 
of China where malaria is no-longer endemic [10]. Most 
anti-PvMSP8 antibodies present in positive responders 
recognize two epitopes located outside of the C termi-
nal EGF-like domain. Furthermore, the cellular immune 
response in P. vivax-infected exposed individuals pro-
duces high levels of IFN-γ and IL-10 upon PvMSP8 
antigen stimulation in vitro [10]. Together, these reports 
indicate an ability of this protein to trigger both cellular 
and humoral immunity. However, further characteri-
zation of the ability of PvMSP8 to stimulate long-term 
immune responses is required before this antigen is pro-
posed as a vaccine candidate in combination with other 
blood stage antigens in malaria vaccine development.
The memory immune response is an essential compo-
nent of adaptive immunity to infective agents, includ-
ing Plasmodium spp. The persistence of malaria-specific 
memory B cells (MBCs) was shown in individuals who 
lived in regions with low malaria endemicity, indicating 
that long-lived MBCs were developed and maintained in 
the absence of re-infection [11, 12]. In contrast, a short-
term response has been observed in regions with high 
malaria endemicity; a response which involved the expan-
sion of atypical MBC subsets resulting in short-lived 
antibody responses [13, 14]. In this study, the ability of 
the PvMSP8 antigen to induce long-term humoral immu-
nity in the absence of parasite stimulation was explored 
using cohort studies. The development and persistence 
of antibody responses were assessed in individuals dur-
ing the acute disease and recovery phase of P. vivax infec-
tions. Long-term responses of PvMSP8-specific MBCs 
were also observed in P. vivax-infected patients who had 
recovered from an infection acquired 4 years previously. 
This study contributes to a better understanding of the 
long-term humoral immune response to P. vivax and will 
be useful in the development of effective malaria vaccines 
in the future.
Methods
Study site and sample collection
Both cross-sectional and longitudinal analyses were 
designed to evaluate the long-term antibody and mem-
ory B cell responses to the PvMSP8 antigen following 
natural P. vivax exposure at Rap Ro, a village near the 
Myanmar border of Southern Thailand where malaria 
transmission is seasonal and peaks during the rainy sea-
son (May to December). Firstly, the seroprevalence of 
antibody to PvMSP8 was assessed using a cross-sectional 
study, between May 2014 and May 2017. Plasma sam-
ples were collected from P. vivax-infected subjects dur-
ing the acute (n = 40) and recovery phases of infection 
[at 3  months (3  months, n = 35), 9  months (9  months, 
n = 26), and 12 months (12 months, n = 25)] to measure 
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antibody levels using an indirect ELISA (Table 1). Of the 
40 acutely infected patients, 16 patients were available 
for sample collection at all time points. These patients 
were included in the sub-cohort 1 study designed to 
assess the longevity of antibody responses to recom-
binant protein and synthesized peptides of PvMSP8 
(Table  2). To further explore the long-term antibody 
responses against this protein post-infection, 5 subjects 
from the total 40 infected patients were further moni-
tored up to 12  months post-infection for anti-PvMSP8 
antibody as the sub-cohort 2 study (between May 2014 
and May 2018). Finally, the persistence of seropositive 
anti-PvMSP8 responses at 4  years post-infection was 
investigated by assessing specific MBC responses in 13 
other patients who had recovered from a P. vivax infec-
tion 4 years earlier (Table 4).
Blood samples used as malaria-naïve controls (n = 20) 
were obtained from healthy volunteers who lived in non-
malariaous areas and had no history of exposure to Plas-
modium parasites. Venous blood samples were collected 
in Vacuette Heparin tubes (Greiner Bio-One, Monroe, 
NC, USA) and transported to the laboratory within 6 h. 
Thick and thin blood smears, as well as nested PCR, were 
used to determine the presence of P. vivax parasites. His-
torical data of previous malaria infections and the num-
ber of P. vivax infections in study subjects were obtained 
from the records of the Vector Borne Disease Unit, based 
on blood smear and nested PCR detection. Patients were 
scheduled for follow-up blood collection every 3 months 
to assess sub-patent malaria by nested PCR. Staff in this 
unit conducted weekly house-to-house visits from May 
2014 to May 2017 (sub-cohort 1) or May 2014 to May 
2018 (sub-cohort 2) to estimate the incidence of clini-
cal malaria over the study period. Ethical approval was 
obtained from the Committee on Human Rights Related 
to Human Experimentation, Mahidol University, Thai-
land (MUIR 2012/079.2408).
Expression of the recombinant PvMSP8 protein
The recombinant PvMSP8 protein was expressed as pre-
viously described [10]. Briefly, P. vivax DNA was ampli-
fied using the specific primers PvMSP8F 5′-GGG CGG 
ATA TCT CGA GGG AAA CGT TAG CCC ACCC-3′; and 
PvMSP8R 5′-GCG GTA CCC GGG ATC CTT AGC AGT 
ATA TTC CGT CTC CCTCA-3′. Then, this PvMSP8 DNA 
was cloned into the pEU-E01-His-TEV-MCS vector 
Table 1 Characteristics of  study participants in  survey of  PvMSP8 antigenicity at  different time points after  P. vivax 
infection
Characteristics P. vivax-infected participants
Acute vivax patients Recovered subjects
3 months 9 months 12 months
Total (n) 40 35 26 25
Gender
 Male 28 24 15 16
 Female 12 11 11 9
Age
 Mean ± SD
37.4 ± 12 40.0 ± 1.4 41.2 ± 12.2 41.1 ± 11.8 
Parasitaemia (parasite/µL)
 Mean ± SD
5170.8 ± 5238.3 0 0 0
No. of prior infections
 0 40 35 25 24
 1 0 0 1 1
 > 1 0 0 0 0
No. of recorded re‑infections 0 0 1 1
Table 2 The history of P. vivax infections in subjects enrolled in the antibody longevity study followed for 12 months
Total number No. of positive responders 
at acute phase (%)




Mean ± SD Male Female 0 1 > 1 Symptomatic infection Asymptomatic infection
16 16 (100%) 44.0 ± 9.35 12 4 15 1 0 1 0
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(CellFree Sciences, Matsuyama, Japan) and expressed 
using a WGCF expression system. The protein was puri-
fied using a Ni–NTA agarose column (Qiagen, Hilden, 
Germany). The production of rPvMSP8 protein was 
detected by western blotting using an anti-penta-His 
antibody (Qiagen).
Detection of the total IgG response to PvMSP8
Anti-PvMSP8 antibody levels in plasma samples from 
patients with acute P. vivax infections and follow-up 
samples collected 3  months, 9  months, 12  months, 
3 years and 4 years after recovery were assayed using an 
enzyme-linked immunosorbent assay (ELISA). Briefly, 
2  µg/mL rPvMSP8 protein was coated onto 96-well 
plates and incubated at 4  °C overnight. The plates were 
then incubated with blocking buffer for 2 h at room tem-
perature (RT) following which 100 μL of plasma diluted 
1:200 in blocking buffer were added to each well and 
incubated for 1 h. After washing the plates five times, a 
1:1000 dilution of goat anti-human IgG-alkaline phos-
phatase in blocking buffer was added to each well. Finally, 
the 2,2-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) 
substrate (Sigma-Aldrich, St. Louis, MI, USA) was added 
to detect antigen–antibody reactivity. Absorbance was 
recorded at 405  nm 1  h after the addition of the devel-
oper reagent. OD values for duplicate wells for each sam-
ple were averaged. A baseline OD was established using 
plasma samples from 20 Thai individuals who were not 
exposed to malaria; this control value was subtracted 
from the test OD values to standardize the assay.
Analysis of long-term antibody responses induced 
by the PvMSP8 peptides
Four peptides were recognized by anti-PvMSP8 antibod-
ies in our previous study [10]. These four synthesized 
peptides (Peptide No. 2: DDSFDLSDYLADFELINY, 
Peptide No. 3: LADFELINYIIMHETSEL, Peptide No. 
4: IIMHETSELIDELINIIE and Peptide No. 5: IDELLNI-
IESMNFRKESG) were used to detect specific antibodies 
in study samples in the 3-year and 4-year cohort stud-
ies, and to determine whether these specific epitopes 
of PvMSP8 induced long-term responses following a 
natural infection. A set of 18-mer peptides spanning the 
conserved C terminus of PvMSP8 Sal-1 sequences, each 
overlapping by nine amino acids, were custom synthe-
sized at > 90% purity, purified, and used for the coating 
step of the ELISA (Peptron Co., Ltd., Daejeon, Korea). 
Peptides were coated onto 96-well plates at a concentra-
tion of 10 μg/mL and incubated at 4 °C overnight. Then, 
the IgG responses to peptides were detected using the 
protocol for the detection of anti-rPvMSP8 antibod-
ies. The cut-off value was calculated as the mean plus 
two SDs of the ODs of the plasma samples from the 20 
healthy controls (HC).
Enzyme-linked immunospot assay (ELISPOT)
Peripheral blood mononuclear cells (PBMCs) were 
adjusted to a concentration of 1 × 106 cells/mL and dis-
tributed into 24-well culture plates. Then, cells were 
stimulated with a mixture of 1  μg/mL R848 and 10  ng/
mL rhIL-2 (Mabtech, Stockholm, Sweden), and cul-
tured with 5%  CO2 at 37  °C for 3  days. The 96-well 
ELISPOT plates (Millipore) were coated with 10 μg/mL 
rPvMSP8 or 1  mg/mL of tetanus toxoid (TT) or 15  μg/
mL mAbMT91/145 (anti-human IgG monoclonal anti-
body) in PBS at 4  °C overnight to detect cells secreting 
PvMSP8-specific antibodies. The wells were blocked with 
R10 (10% FBS in RPMI 1640 media) at RT for 1 h. Stim-
ulated PBMCs were harvested, washed and incubated 
in PvMSP8 antigen-coated ELISPOT wells for 16–24  h. 
The wells were washed and incubated with 100 μL of 
1  μg/mL mAb MT78/145 (biotinylated anti-human IgG 
monoclonal antibodies) at RT for 2 h. After washes with 
PBS, 100 μL of streptavidin-conjugated HRP was added 
and incubated at RT for 1 h. The plate was washed and 
100 μL of TMB substrate solution were used to detect the 
spots. After 10 min, the enzymatic reaction was stopped 
by rinsing the plate with deionized water. Spots were 
counted using a Bioreader 5000 Pro-F gamma ELISPOT 
Reader (BioSys GmbH, Germany). A positive response of 
antigen-specific MBCs was defined as spot-forming cells 
(SFCs) with a twofold or greater total number of spots 
than that of the negative controls.
Statistical analysis
Total IgG responses to recombinant PvMSP8 or synthe-
sized peptides were compared between unpaired groups 
(acute disease compared to recovery, or patient com-
pared to healthy controls) using the Mann–Whitney U 
test. Statistical analysis was performed and graphs pre-
pared using GraphPad Prism software (v. 5; GraphPad 
Software, San Diego, CA, USA).
Results
Prevalence of anti-PvMSP8 IgG levels in the acute 
and recovery phases of P. vivax infections
The cross-sectional survey of MSP8 antigenicity was 
conducted during the acute and recovery phases of 
infection (Table 1). During symptomatic malaria, anti-
PvMSP8 IgG levels were significantly higher than lev-
els in malaria-naïve persons (Fig. 1). During follow-up, 
positive antibody responses to PvMSP8 in previously 
P. vivax-infected patients (3, 9, and 12  months after 
infection) were found in high numbers of subjects. 
Approximately 89%, 62% and 84% of these subjects 
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were seropositive at 3, 9, and 12  months, respectively 
(Fig. 1). Based on these data, patients tended to main-
tain serological responses to PvMSP8 after recovery 
from infection. To add to this, the antibody responses 
in P. vivax-infected individuals were analysed over a 
longer post-infection period.
Prevalence of anti-IgG PvMSP8 antibodies through 4 years 
post-infection
Sixteen patients in the sub-cohort 1 study were ana-
lysed to detect anti-PvMSP8 antibody levels and deter-
mine the longevity of anti-PvMSP8 responses after 
infection (Table  2). Although anti-PvMSP8 IgG levels 
were significantly reduced at 9  months post-infection 
compared to the acute phase, 63% of samples remained 
seropositive (Fig. 2a). Monitoring of anti-PvMSP8 IgG 
levels in these individuals was continued for 12 months. 
Eleven patients (69%) continued to be positive for anti-
PvMSP8 antibody (Fig.  2b). The persistence of long-
lived anti-PvMSP8 antibody responses was further 
examined by following five P. vivax-infected patients 
until 4  years post-infection in the sub-cohort 2 study. 
These 4 patients maintained seropositivity at the 4 years 
time point (Fig. 2c). Based on the results of these lon-
gitudinal analyses, PvMSP8 induces antibodies, which 
persist after recovery from infection.
Long-term antibody responses to specific PvMSP8 B cell 
epitopes following infection
Four predominant epitopes of PvMSP8 have been iden-
tified as targets of acquired anti-PvMSP8 antibodies 
in patients with an acute P. vivax infection [10]. It was 
hypothesized that the antibody responses to these B cell 
epitopes may persist in the long-term. In fact, the patients 
with acute vivax malaria produced significant antibody 
responses to peptide Nos. 2, 3 and 5 of the PvMSP8 pro-
tein (Fig.  3a–d) and 6 patients showed preferential rec-
ognition to one of these three peptides. Moreover, broad 
reactivity of anti-peptide antibodies was found as there 
were 2, 3 and 1 patients who were seropositive to 2, 3 and 
4 peptides of PvMSP8 protein, respectively (Table 3). The 
further monitoring anti-PvMSP8 peptide antibody lev-
els in seropositive patients for 12 months post-infection 
showed that 3 patients maintained antibody responses to 
peptide No. 2. Interestingly, one patient (Pv30) was found 
for anti-peptide Nos. 3 and 5 antibodies (Fig. 3e–g).
Long-lived PvMSP8-specific MBCs were detected at 4 years 
post-infection
The maintenance of circulating antibodies is indepen-
dently related to the response of long-lived plasma cells 
in subjects with malaria [12]. Thus, the long-term anti-
PvMSP8 antibody responses in some patients who had 
recovered from infection 4  years earlier were linked to 
Fig. 1 Antibody responses to PvMSP8 in the acute disease stage and after infection. A cross‑sectional survey was used to explore the 
seroprevalence of the antibody response in symptomatic patients with a P. vivax infection (n = 40) and after recovery from infection for 3 (n = 35), 
9 (n = 26), and 12 (n = 25) months compared to healthy controls (HC, n = 20). The filled circles represent the subjects that were used for the 
longitudinal analysis. The cut‑off value was calculated from the mean plus 2 SDs of the OD for HC. AC, acute phase; HC, healthy controls
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the persistence of PvMSP8-specific MBCs (Table  4). Of 
the 13 total patients, samples from 9 patients showed 
positive PvMSP8-specific MBCs in the ELISPOT assay. 
The average frequency of PvMSP8-specific MBCs among 
responders was 13 PvMSP8-specific MBCs per million 
PBMCs, with a range of 5–21 PvMSP8-specific MBCs per 
million PBMCs (Fig.  4). Interestingly, PvMSP8-specific 
MBCs were produced in the majority (n = 9) of patients 
who were initially infected with P. vivax. Six responders 
who had positive PvMSP8-specific MBCs also had posi-
tive antibody titers to PvMSP8. However, the presence of 
long-lived MBCs was not consistently related to antibody 
response, as 3 seronegative subjects had positive MBC 
responses.
Discussion
The challenge in the development of a malaria vac-
cine is the requirement to induce long-term protective 
immunity. To date, the data provided by immuno-epi-
demiological studies have prompted debate regarding 
whether naturally acquired MBCs develop during an 
infection and whether those MBCs persist in the absence 
of re-infection. In this study, cross-sectional and cohort 
studies were designed to observe the development and 
persistence of antibodies and MBCs specific for the 
blood stage PvMSP8 antigen to address this hypothesis. 
The serological response to PvMSP8 was prominent 
during acute P. vivax infections as 89% of patients were 
seropositive to the antigen. After infection, the majority 
of patients maintained the anti-PvMSP8 response for up 
to 12 months. Interestingly, positive antibody responses 
were also detected in 80% of patients 4 years post-infec-
tion. Similarly, the PvMSP8-specific MBCs were positive 
in approximately 69% of P. vivax-infected subjects 4 years 
after their infections. Based on these data, long-term 
humoral immune responses to PvMSP8 developed and 
were maintained in individuals living in this low malaria 
endemic region. However, the relationship between the 
longevity of anti-PvMSP8 responses and protection from 
infection and symptom severity given infection requires 
Fig. 2 Longitudinal analysis of anti‑PvMSP8 responses. The longevity of anti‑PvMSP8 responses is shown in a, b for P. vivax‑infected patients in the 
12‑month cohort study (n = 16) and c for subjects in the 4‑year cohort study (n = 5). The cut‑off value was calculated from the mean plus 2 SDs of 
the OD for HC
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Fig. 3 The durability of antibody responses to predominant PvMSP8 peptides. a–d The frequencies of antibody responses to PvMSP8 peptide 
Nos. 2, 3, 4 and 5 in patients with an acute P. vivax infection (n = 16) compared to HC (n = 16). e–g Antibody responses to PvMSP8 peptides in 
seropositive patients, peptide No. 2 (n = 6), peptide No. 3 (n = 7), and peptide No. 5 (n = 5), at acute infection and three follow‑up times in the 
cohort study (AC, 3 months, 9 months and 12 months post‑infection). The cut‑off value was calculated as the mean plus 2 SDs of the OD for HC
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validation in other cohorts and exploration in model 
systems.
The immunogenicity of the MSP8 antigen has been 
reported in patients with both P. falciparum and P. vivax-
induced malaria. Surprisingly, immune responses to 
PvMSP8 were detectable  12  years after the last malaria 
episode in some individuals residing in an area that 
was no longer endemic for malaria [5, 10]. However, a 
cross-sectional study might be not sufficient to confirm 
the results of a longitudinal immunological analysis. 
Therefore, cohort studies are better able to add to the 
understanding of the establishment and maintenance of 
anti-PvMSP8 antibody responses. Here, 69% of patients 
in the cohort study were seropositive at 12 months post-
infection, representing a long-term response that devel-
oped during the acute phase. In addition, some had 
PvMSP8-specific MBCs which persisted for up to 4 years 
after infection. However, the levels of anti-PvMSP8 
antibodies were not correlated with parasitaemia in 40 
acutely infected patients. Although PvMSP8 is not local-
ized on the merozoite surface, this protein is essential 
for constructing the parasitophorous vacuole during the 
ring stage by being redistributed to the parasite surface 
just prior to or following invasion of RBCs [5, 6]. Thus, 
Table 3 The pattern analysis of  antibody responses 
to  synthetic MSP8 peptides in  16 patients with  acute P. 
vivax infection
+ indicates positive response to one or more synthetic MSP8 peptides








PV1 − − − +
PV2 + − − −
PV3 − + − −
PV4 − − − −
PV5 + + − −
PV6 − − − −
PV30 + + + +
PV31 − − + −
PV32 − − − −
PV33 − + + −
PV34 − − − −
PV35 + + − +
PV36 + − + +
PV37 − − + −
PV39 + + − +
PV40 − + − −
Total 6 7 5 5
Table 4 The history of P. vivax infections in subjects enrolled in the PvMSP8-specific MBC study between 2014 and 2018
ELISPOT results Age
(mean ± SD)
Gender No. of previous infections No. of recorded re-infections




Positive 47 ± 13.3 5 4 8 1 0 1 0
Negative 35.5 ± 15.2 1 3 4 0 0 0 0
Fig. 4 PvMSP8‑specific MBC responses at 4 years post‑infection. The numbers of specific MBCs produced in response to a PvMSP8, b tetanus toxoid 
(TT), and total IgG in PBMCs from subjects that persisted 4 years after the P. vivax infection were determined using an ELISPOT assay (n = 13). The 
frequencies of MBCs were determined by counting the number of spots that appeared per million cultured PBMCs. Each symbol represents the 
MBC number for one individual. The line represents the median value
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naturally acquired anti-PvMSP8 antibody responses 
could be involved in (i) the inhibiting of merozoite inva-
sion into RBCs, (ii) blocking cytoadherence of infected 
RBCs to endothelial cells, and/or (iii) enhancing the 
phagocytic activity of monocytes and macrophages [15, 
16]. On the other hand, MSP8 protein may act as a par-
asite-specific carrier protein to enhance the production 
of complex malaria vaccine targets such as MSP1, apical 
membrane antigen 1 and DBPII. It has been reported that 
PfMSP8-specific protein carrier can enhance the immu-
nogenicity of neutralizing B cell epitopes in the 19-kDa 
C terminal domain of PfMSP1, and has potent transmis-
sion-reducing activity upon the fusion of PfMSP8 with 
the Pfs25 gamete antigen [8, 17]. Insight into the lon-
gevity of responses and the protective role of anti-MSP8 
antibodies will be an important information for further 
development of blood stage malaria vaccine.
A synthetic peptide-based vaccine encompassing mul-
tiple protective epitopes that occur in difference stages 
of the malaria life cycle is considered a new strategic 
approach in vaccine development [18]. The MSP8 protein 
contains immunogenic epitopes of both T and B cells. The 
C terminus is involved in T cell responses [7], whereas 
outside the C terminal EGF-like domain is a region of B 
cell epitopes mapped by highly reactive patient sera [10]. 
These data suggest that MSP8 epitopes induce both T 
and B cell responses upon stimulation, as during natu-
ral infection. Thus, it was these predominant epitopes 
[10], which were assessed further in this study to observe 
whether the resulting antibody responses were main-
tained after infection. The longevity of anti-PvMSP8 pep-
tide responses was addressed with this 12-month cohort 
study. Antibody responses against peptide Nos. 2, 3 and 
5 fell over time and became seronegative at 9  months 
post-infection. Only 3 patients and 1 patient maintained 
detectable positive antibody responses against peptide 
Nos. 2 and 3, respectively. These three peptides, in the 
context of combinations or fusions of PvMSP8 peptides, 
may enhance or synergize long-term immune responses 
against blood stage antigens and should be considered for 
further study and possible vaccine design.
The maintenance of long-term humoral immunity 
against PvMSP8 in the absence of repeated antigen stimu-
lation was demonstrated in the present study. Nine of 13 
patients showed long-lived MSP8-specific MBCs at 4 years 
post-infection in the cohort study. Among the positive 
responders, 8 patients were experiencing their first P. vivax 
infection, an observation consistent with previous reports 
of Peruvian patients who produced MBCs specific to 
PfMSP1 [19] and Thai P. vivax-infected patients who pro-
duced MBCs specific to PvMSP1 paralog-19 and PvDBPII 
[11, 20]. Thus, individuals living in regions with low rates 
of malaria transmission might generate PvMSP8-specific 
MBCs even after a single infection. Interestingly, the 
boosting capacity of the humoral immune system against 
PvMSP8 may have been demonstrated by subject Pv03 
whose P. vivax re-infection was associated with a high fre-
quency of MSP8-specific MBCs (approximately 21 spots 
per million cells) (Fig.  3c). Moreover, MBCs specific to 
synthesized peptides Nos. 2 and 4 were detected in indi-
viduals who were ELISPOT positive to rPvMSP8, indicat-
ing that long-lived MBCs were acquired following natural 
exposure to the P. vivax parasite.
The goal of effective vaccine development is to produce 
a safe product, which induces or stimulates long-term 
protection. In studies of malaria, longitudinal cohort-
designed studies of individuals who live in endemic 
regions are required to obtain a better understanding 
of the long-term immunity, which occurs in response 
to natural infections. Here, the presence of long-lived 
antibodies and MBCs specific to the PvMSP8 protein 
was examined using both cross-sectional and longitudi-
nal studies. In the 12-month cohort study, seropositive 
antibody responses were maintained in a majority of P. 
vivax-infected patients, and these responses persisted 
for up to 4 years in some patients. In the 4-year cohort 
study, the antibody responses were related to the pres-
ence of PvMSP8-specific MBCs. Encouragingly, this 
study provided evidence that patients developed long-
term humoral immune responses to the malaria antigen 
PvMSP8. Thus, this antigen might be added to existing, 
but only partially effective, candidate vaccines to develop 
products with greater efficacy.
The present study was limited by the inability to recruit 
a large number of P. vivax subjects into a cohort study; 
16 and 13 patients were enrolled and followed for 1- and 
4 years, respectively. Thus, these observations should be 
considered preliminary in their demonstration that anti-
PvMSP8 antibodies and specific MBCs are stably pres-
ence in the absence of reinfection. A study with a larger 
sample size and improved surveillance would help to 
confirm these findings of long-term protective immunity 
induced by this P. vivax malaria antigen.
Conclusions
This study reveals the antigenicity of the PvMSP8 pro-
tein and its ability to induce long-term humoral immune 
responses. These anti-PvMSP8 responses generally per-
sisted for at least 12  months post-infection and were 
maintained in some patients for up to 4  years. Impor-
tantly, the persistence of the antibody response was 
related to the presence of PvMSP8-specific MBCs in 
the patient’s antibody positive at 4  years post-infection. 
In sum, PvMSP8 antigen-specific antibodies and MBCs 
developed and persisted in individuals living in an area of 
low malaria transmission.
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